|  |  |  |
| --- | --- | --- |
|  | **Cohort A**a | **Cohort B**b |
| **Safety population, n** | 46 | 11 |
| **Efficacy-evaluable population, n** | 45 | 9 |
| **BPI-evaluable population, n** | 46 | 9 |
| **Median treatment duration, months** | 7.9 | 5.7 |
| **Best overall response, n (%)**c |  |  |
| Partial response | 22 (49) | 4 (44) |
| Stable disease | 23 (51) | 5 (56) |
| **Objective response rate, n (%)** | 22 (49) | 4 (44) |
| **BPI, n (%)**d |  |  |
| Worst pain improvement | 22 (48) | 6 (67) |
| Average pain improvement | 24 (52) | 6 (67) |
| aNo prior anti-CSF1/CSF1R therapy.  bPrior anti-CSF1/CSF1R therapy.  cUsing RECIST v1.1 by independent radiologic review; includes all available follow up. Data are maturing and will be updated.  dImprovement: ≥30% reduction in tumour associated pain at Week 25. | | |